Dietary and Pharmacological Treatment of Nonalcoholic Fatty Liver Disease

• Published in: Medicina (Kaunas, Lithuania) Lithuania), 2019-05, Vol.55 (5), p.166
• Main Authors: Jeznach-Steinhagen, Anna, Ostrowska, Joanna, Czerwonogrodzka-Senczyna, Aneta, Boniecka, Iwona, Shahnazaryan, Urszula, Kuryłowicz, Alina
• Format: Article
• Language: English
• Subjects: antidiabetic agents; Diabetes Mellitus - drug therapy; Diabetes Mellitus - physiopathology; diet; Humans; Hypoglycemic Agents - therapeutic use; Insulin Resistance; Non-alcoholic Fatty Liver Disease - diet therapy; Non-alcoholic Fatty Liver Disease - drug therapy; nonalcoholic fatty liver disease (NAFLD); Nutritional Status; physical activity; Prebiotics; Probiotics - therapeutic use; Review
• ISSN: 1648-9144; 1010-660X; 1648-9144; 1010-660X
• DOI: 10.3390/medicina55050166

Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in the developed world. Simple hepatic steatosis is mild, but the coexistence of steatohepatitis (NASH) and fibrosis increases the risk of hepatocellular carcinoma. Proper dietary and pharmacological treatment is essential for preventing NAFLD progression. The first-line treatment should include dietary intervention and increased physical activity. The diet should be based on the food pyramid, with a choice of products with low glycemic index, complex carbohydrates in the form of low-processed cereal products, vegetables, and protein-rich products. Usage of insulin-sensitizing substances, pro- and prebiotics, and vitamins should also be considered. Such a therapeutic process is intended to support both liver disease and obesity-related pathologies, including insulin resistance, diabetes, dyslipidemia, and blood hypertension. In the pharmacological treatment of NAFLD, apart from pioglitazone, there are new classes of antidiabetic drugs that are of value, such as glucagon-like peptide 1 analogs and sodium/glucose cotransporter 2 antagonists, while several other compounds that target different pathogenic pathways are currently being tested in clinical trials. Liver biopsies should only be considered when there is a lack of decline in liver enzymes after 6 months of the abovementioned treatment. Dietary intervention is recommended in all patients with NAFLD, while pharmacological treatment is recommended especially for those with NASH and showing significant fibrosis in a biopsy.